Bristol rises on 2025 guidance raises, Q3 beats driven by Eliquis growth

5 hours ago 1
3rd quarter growth

honglouwawa

Bristol Myers Squibb (BMY) is up ~5% in Thursday trading after boosting its 2025 revenue and EPS guidance following the release of its Q3 financial results that beat on both lines.

The pharma now sees adjusted EPS for the year

Recommended For You

More Trending News

Read Entire Article